The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: Relationship with clinicopathological parameters

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ngollo, Marjolaine ^a,b   Lebert, Andre ^b   Dagdemir, Aslihan ^a,b   Judes, Gaelle ^a,b   Karsli Ceppioglu, Seher ^a,b   Daures, Marine ^a,b   Kemeny, Jean Louis ^c   Penault Llorca, Frederique ^a,b   Boiteux, Jean Paul ^c   Bignon, Yves Jean ^a,b   Guy, Laurent ^b,c   Bernard Gallon, Dominique ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Chromatin immunoprecipitation; Epigenetic; Histone modifications; Prostate cancer; Trimethylation

Indexed keywords

HISTONE H3; LYSINE; MESSENGER RNA; PROGESTERONE RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR EZH2; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HISTONE; NCOA3 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; RARB2 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; ER ALPHA GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MIDDLE AGED; PROMOTER REGION; PROSTATE CANCER; RAR BETA 2 GENE; RGMA GENE; SRC3 GENE; UPREGULATION; CANCER GRADING; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROSTATE TUMOR;

DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; NEOPLASM GRADING; NUCLEAR RECEPTOR COACTIVATOR 3; POLYCOMB REPRESSIVE COMPLEX 2; PRINCIPAL COMPONENT ANALYSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, RETINOIC ACID;

EID: 84926432769     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2261-14-162     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Majumdar S, Buckles E, Estrada J, Koochekpour S: Aberrant DNA methylation and prostate cancer. Curr Genomics 2011, 12:486-505.
3. Adjakly M, Bosviel R, Rabiau N, Boiteux J-P, Bignon Y-J, Guy L, Bernard-Gallon D: DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics 2011, 3:795-803.
4. Dagdemir A, Durif J, Ngollo M, Bignon Y-J, Bernard-Gallon D: Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics 2013, 5:51-63.
5. Rabiau N, Trraf H-K, Adjakly M, Bosviel R, Guy L, Fontana L, Bignon Y-J, Bernard-Gallon DJ: miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo 2011, 25:917-921.
6. You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012, 22:9-20.
7. Chen Z, Wang L, Wang Q, Li W: Histone modifications and chromatin organization in prostate cancer. Epigenomics 2010, 2:551-560.
8. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH-M, Issa J-PJ: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008, 40:741-750.
9. Kerppola TK: Polycomb group complexes-many combinations, many functions. Trends Cell Biol 2009, 19:692-704.
10. Richly H, Aloia L, Di Croce L: Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2011, 2:e204.
11. Cavalli G: Molecular biology. EZH2 goes solo. Science 2012, 338:1430-1431.
12. Varambally S, Cao Q, Mani R-S, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
13. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM: Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011, 2:669-683.
14. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang B-D, Andrawis R, Lee NH, Apprey V, Issa J-P, Ittmann M: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res Off J Am Assoc Cancer Res 2010, 16:3539-3547.
15. Moison C, Senamaud-Beaufort C, Fourrière L, Champion C, Ceccaldi A, Lacomme S, Daunay A, Tost J, Arimondo PB, Guieysse-Peugeot A-L: DNA methylation associated with polycomb repression in retinoic acid receptor ß silencing. FASEB J Off Publ Fed Am Soc Exp Biol 2013, 27:1468-1478.
16. Nishimori H, Ehata S, Suzuki HI, Katsuno Y, Miyazono K: Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J Biol Chem2012, 287:20037-20046.
17. Li J, Ye L, Kynaston HG, Jiang WG: Repulsive guidance molecules, novel bone morphogenetic protein co-receptors, are key regulators of the growth and aggressiveness of prostate cancer cells. Int J Oncol 2012, 40:544-550.
18. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, VidaudM: Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001, 61:1919-1926.
19. Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, Bishop MC, Rees RC: Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. The Prostate 2009, 69:810-819.
20. Zhou H-J, Yan J, Luo W, Ayala G, Lin S-H, Erdem H, Ittmann M, Tsai SY, Tsai M-J: SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005, 65:7976-7983.
21. Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433-440.
22. Rabiau N, Thiam MO, Satih S, Guy L, Kemeny J-L, Boiteux J-P, Fontana L, Bignon Y-J, Bernard-Gallon D: Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo 2009, 23:387-391.
23. Vardi A, Bosviel R, Rabiau N, Adjakly M, Satih S, Dechelotte P, Boiteux J-P, Fontana L, Bignon Y-J, Guy L, Bernard-Gallon DJ: Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo 2010, 24:393-400.
24. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
25. Ngollo M, Dagdemir A, Judes G, Kemeny J-L, Penault-Llorca F, Boiteux J-P, Lebert A, Bignon Y-J, Guy L, Bernard-Gallon D: Epigenetics of Prostate Cancer: Distribution of Histone H3K27me3 Biomarkers in Peri-Tumoral Tissue. Omics 2014, 18:207-209.
26. Steiner I, Jung K, Schatz P, Horns T,Wittschieber D, Lein M, Dietel M, Erbersdobler A: Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiol J Immunopathol Mol Cell Biol 2010, 77:260-266.
27. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
28. Yang YA, Yu J: EZH2, an epigenetic driver of prostate cancer. Protein Cell 2013, 4:331-341.
29. Rabiau N, Déchelotte P, Adjakly M, Kemeny J-L, Guy L, Boiteux J-P, Kwiatkowski F, Bignon Y-J, Bernard-Gallon D: BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection. Oncol Rep 2011, 26:695-702.
30. Prins GS, Korach KS: The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73:233-244.
31. Rabiau N, Dantal Y, Guy L, Ngollo M, Dagdemir A, Kemeny J-L, Terris B, Vieillefond A, Boiteux J-P, Bignon Y-J, Bernard-Gallon D: Gene panel model predictive of outcome in patients with prostate cancer. Omics J Integr Biol 2013, 17:407-413.
32. Li VSW, Yuen ST, Chan TL, Yan HHN, Law WL, Yeung BHY, Chan ASY, Tsui WY, So S, Chen X, Leung SY: Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. Gastroenterology 2009, 137:176-187.
33. Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T: The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Investig J Tech Methods Pathol 2001, 81:1049-1057.
34. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002, 8:514-519.
35. Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000, 60:3175-3182.
36. Daniels G, Gellert LL, Melamed J, Hatcher D, Li Y, Wei J, Wang J, Lee P: Decreased expression of stromal estrogen receptor a and ß in prostate cancer. Am J Transl Res 2014, 6:140-146.
37. Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON: Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res 2012, 72:4672-4681.
38. Cha T-L, Zhou BP, Xia W, Wu Y, Yang C-C, Chen C-T, Ping B, Otte AP, Hung M-C: Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310:306-310.
39. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM: Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007, 6:51-60.
40. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005, 4:1311-1319.
41. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL: Histone deacetylases are required for androgen receptor function in hormonesensitive and castrate-resistant prostate cancer. Cancer Res 2009, 69:958-966.
42. Bjurlin MA, Taneja SS: Standards for prostate biopsy. Curr Opin Urol 2014, 24:155-161.
43. R Development Core Team: R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
44. Mendiburu F: agricolae: Statistical Procedures for Agricultural Research. R package version 1.1.4. 2013. http://CRAN.R-project.org/package=agricolae.
45. Heiberger RM: HH:Statistical Analysis and Data Display. New York, USA: Springer Science; 2013.
46. Torsten H, Bretz F, Westfall P, Heiberger RM: Multcomp: Simultaneous Inference in General Parametric Models. Biometrical Journal 2014, 50:346-363.
47. Raykov T, Marcoulides GA: An introduction to applied multivariate analysis. New York, USA: Routledge; 2008.
48. Husson F, Josse J, Le S, Mazt J: FactoMineT: Multivariate Exploratory Data Analysis and Data Mining with R. R package version 1.25. Journal of statistical Software 2013, 25:1-18.
49. Brown TA, Wicker LR: Discriminant Analysis in Handbook of Applied Multivariate Statistics and Mathematical Modeling. Edited by Tinsley HEA, Brown SD. California, USA: Elsevier Science & Technology Books; 2000.
50. Todorov V, Filzmoser P: rrcov() an Object-Oriented Framework for Robust Multivariate Analysis. Journal of Statistical Software 2009, 32(3):1-47.